- Home
- BCTX vs GROW Comparison
BCTX vs GROW Comparison
Compare BCTX & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- GROW
- Stock Information
- Founded
- BCTX 2014
- GROW 1968
- Country
- BCTX Canada
- GROW United States
- Employees
- BCTX N/A
- GROW N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- GROW Investment Managers
- Sector
- BCTX Health Care
- GROW Finance
- Exchange
- BCTX Nasdaq
- GROW Nasdaq
- Market Cap
- BCTX 34.6M
- GROW 32.9M
- IPO Year
- BCTX N/A
- GROW N/A
- Fundamental
- Price
- BCTX $0.41
- GROW $2.43
- Analyst Decision
- BCTX Strong Buy
- GROW
- Analyst Count
- BCTX 1
- GROW 0
- Target Price
- BCTX $15.00
- GROW N/A
- AVG Volume (30 Days)
- BCTX 977.6K
- GROW 21.2K
- Earning Date
- BCTX 03-17-2025
- GROW 02-06-2025
- Dividend Yield
- BCTX N/A
- GROW 3.70%
- EPS Growth
- BCTX N/A
- GROW N/A
- EPS
- BCTX N/A
- GROW 0.12
- Revenue
- BCTX N/A
- GROW $10,008,000.00
- Revenue This Year
- BCTX N/A
- GROW N/A
- Revenue Next Year
- BCTX N/A
- GROW N/A
- P/E Ratio
- BCTX N/A
- GROW $20.10
- Revenue Growth
- BCTX N/A
- GROW N/A
- 52 Week Low
- BCTX $0.37
- GROW $2.38
- 52 Week High
- BCTX $4.37
- GROW $2.95
- Technical
- Relative Strength Index (RSI)
- BCTX 36.36
- GROW 49.81
- Support Level
- BCTX $0.38
- GROW $2.41
- Resistance Level
- BCTX $0.42
- GROW $2.49
- Average True Range (ATR)
- BCTX 0.05
- GROW 0.04
- MACD
- BCTX 0.00
- GROW 0.00
- Stochastic Oscillator
- BCTX 12.86
- GROW 33.33
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.